A clinical trial protocol to evaluate the safety and pharmacokinetics of subcutaneously administered immunoglobulin in patients with primary immunodeficiency
Abstract
This protocol is excerpted from recent clinical trials used to study the pharmacokinetics, safety, and tolerability of subcutaneously administered immunoglobulin (SCIG) in subjects with primary immunodeficiency. The primary objective is to determine the weekly dose of SCIG product that produces a steady-state area under the concentration-time curve of total immunoglobulin G level that is non-inferior to that of regularly administered intravenous immunoglobulin (IVIG). We include details of the target population, eligibility criteria, treatment phases, key assessments and procedures, and study analyses. Given that IVIG may be problematic in patients with poor venous access or those who develop systemic adverse effects, among others, the development of SCIG for use in the home setting provides an alternative treatment technique for adults and children with primary immunodeficiency.
Statement of novelty: This protocol describes the main topics found in prospective clinical studies evaluating the safety and pharmacokinetics of SCIG in subjects with primary immunodeficiency.
Formats available
You can view the full content in the following formats:
REFERENCES
Berger M. and Allen J.A. 2015. Optimizing IgG therapy in chronic autoimmune neuropathies: A hypothesis driven approach. Muscle Nerve. 51:315–326.
Berger M., Rojavin M., Kiessling P., and Zenker O. 2011. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin. Immunol. 139:133–141.
Berger M., Jolles S., Orange J.S., and Sleasman J.W. 2013. Bioavailability of IgG administered by the subcutaneous route. J. Clin. Immunol. 33:984–990.
Bonilla F.A. and Geha R.S. 2003. 12. Primary immunodeficiency diseases. J. Allergy Clin. Immunol. 111:S571–S581.
Bruton O.C. 1952. Agammaglobulinemia. Pediatrics. 9:722–728.
Ochs H.D., Gupta S., Kiessling P., Nicolay U., Berger M., and the Subcutaneous IgG Study Group. 2006. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 26:265–273.
Orange J.S., Belohradsky B.H., Berger M., Borte M., Hagan J., Jolles S., Wasserman R.L., Baggish J.S., Saunders R., and Grimbacher B. 2012. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin. Exp. Immunol. 169:172–181.
Picard C., Al-Herz W., Bousfiha A., Casanova J.L., Chatila T., Conley M.E., Cunningham-Rundles C., Etzioni A., Holland S.M., Klein C., Nonoyama S., Ochs H.D., Oksenhendler E., Puck J.M., Sullivan K.E., Tang M.L., Franco J.L., and Gaspar H.B. 2015. Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J. Clin. Immunol. 35:696–726.
Radinsky S. and Bonagura V.R. 2003. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J. Allergy Clin. Immunol. 112:630–633.
Resnick E.S. and Cunningham-Rundles C. 2012. The many faces of the clinical picture of common variable immune deficiency. Curr. Opin. Allergy Clin. Immunol. 12:595–601.
Roifman C.M. and Gelfand E.W. 1988. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr. Infect. Dis. J. 7:S92–S96.
Stiehm E.R., Casillas A.M., Finkelstein J.Z., Gallagher K.T., Groncy P.M., Kobayashi R.H., Oleske J.M., Roberts R.L., Sandberg E.T., and Wakim M.E. 1998. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product. J. Allergy Clin. Immunol. 101:848–849.
Wang W., Wang E.Q., and Balthasar J.P. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84:548–558.
Wasserman R.L., Irani A.M., Tracy J., Tsoukas C., Stark D., Levy R., Chen J., Sorrells S., Roberts R., and Gupta S. 2010. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin. Exp. Immunol. 161:518–526.
Wasserman R.L., Melamed I., Nelson R.P. Jr., Knutsen A.P., Fasano M.B., Stein M.R., Rojavin M.A., and Church J.A. 2011. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin. Pharmacokinet. 50:405–414.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 6 • Number 2 • June 2019
Pages: 75 - 86
History
Received: 11 April 2019
Accepted: 16 May 2019
Accepted manuscript online: 22 May 2019
Copyright
© 2019.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
LindaVong. 2019. A clinical trial protocol to evaluate the safety and pharmacokinetics of subcutaneously administered immunoglobulin in patients with primary immunodeficiency. LymphoSign Journal.
6(2): 75-86. https://doi.org/10.14785/lymphosign-2019-0005
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
